Integrating Early Economic Evaluation into Target Product Profile development for medical tests: advantages and potential applications

被引:5
作者
Cocco, Paola [1 ]
Messenger, Michael Paul [2 ]
Smith, Alison Florence [1 ,3 ]
West, Robert Michael [2 ]
Shinkins, Bethany [1 ,3 ]
机构
[1] Univ Leeds, Acad Unit Hlth Econ, Test Evaluat Grp, Leeds, W Yorkshire, England
[2] Univ Leeds, Leeds Inst Hlth Sci, Fac Med & Hlth, Leeds, W Yorkshire, England
[3] NIHR Leeds In Vitro Diagnost Cooperat MIC, Leeds, W Yorkshire, England
基金
英国生物技术与生命科学研究理事会; 英国工程与自然科学研究理事会; 英国医学研究理事会;
关键词
Economic models; Medical tests; Technology assessment; Research and development; COST-EFFECTIVENESS; HEALTH TECHNOLOGIES; PROMISES;
D O I
10.1017/S0266462321000374
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Target Product Profiles (TPPs) outline the characteristics that new health technologies require to address an unmet clinical need. To date, published TPPs for medical tests have focused on infectious diseases, mostly in the context of low- and middle-income countries. Recently, there have been calls for a broader use of TPPs as a mechanism to ensure that diagnostic innovation is aligned with clinical needs, yet the methodology underpinning TPP development remains suboptimal. Here, we propose that early economic evaluation (EEE) should be integrated within the TPP methodology to create a more rigorous framework for the development of "fit-for-purpose" tests. We discuss the potential benefits that EEE could bring to the core activities underpinning TPP development-scoping, drafting, consensus building, and updating-and argue that using EEE to help inform TPPs provides a more objective, evidence-based, and transparent approach to defining test specifications.
引用
收藏
页数:5
相关论文
共 25 条
[1]   Early Economic Evaluation of Diagnostic Technologies: Experiences of the NIHR Diagnostic Evidence Co-operatives [J].
Abel, Lucy ;
Shinkins, Bethany ;
Smith, Alison ;
Sutton, Andrew J. ;
Sagoo, Gurdeep S. ;
Uchegbu, Ijeoma ;
Allen, A. Joy ;
Graziadio, Sara ;
Moloney, Eoin ;
Yang, Yaling ;
Hall, Peter .
MEDICAL DECISION MAKING, 2019, 39 (07) :857-866
[2]   Is stratification testing for treatment of chronic obstructive pulmonary disease exacerbations cost-effective in primary care? an early cost-utility analysis [J].
Abel, Lucy ;
Dakin, Helen A. ;
Roberts, Nia ;
Ashdown, Helen F. ;
Butler, Chris C. ;
Hayward, Gail ;
Van den Bruel, Ann ;
Turner, Philip J. ;
Yang, Yaling .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (02) :116-125
[3]   THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS [J].
Buisman, Leander R. ;
Rutten-van Moelkn, Maureen P. M. H. ;
Postmus, Douwe ;
Luime, Jolanda J. ;
Uyl-de Groot, Carin A. ;
Redekop, William K. .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2016, 32 (1-2) :46-53
[4]  
Cancer Research UK, EARL DET DIAGN CANC
[5]   Target Product Profiles for medical tests: a systematic review of current methods [J].
Cocco, Paola ;
Ayaz-Shah, Anam ;
Messenger, Michael Paul ;
West, Robert Michael ;
Shinkins, Bethany .
BMC MEDICINE, 2020, 18 (01)
[6]  
Dowdy DW, 2008, INT J TUBERC LUNG D, V12, P1021
[7]   Addressing the challenges of diagnostics demand and supply: insights from an online global health discussion platform [J].
Engel, Nora ;
Wachter, Keri ;
Pai, Madhukar ;
Gallarda, Jim ;
Boehme, Catharina ;
Celentano, Isabelle ;
Weintraub, Rebecca .
BMJ GLOBAL HEALTH, 2016, 1 (04)
[8]   Economic evaluation of medical tests at the early phases of development: a systematic review of empirical studies [J].
Frempong, Samuel N. ;
Sutton, Andrew J. ;
Davenport, Clare ;
Barton, Pelham .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (01) :13-23
[9]  
Frempong SN., 2019, PHARMACOECONOMICS, V4, P143
[10]  
Grutters JPC, 2019, INT J HEALTH POLICY, V8, P575, DOI [10.15171/ijhpm.2019.36, 10.15171/IJHPM.2019.36]